255 related articles for article (PubMed ID: 35314506)
1. Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
Josephs KA; Weigand SD; Whitwell JL
Neurology; 2022 May; 98(22):e2282-e2292. PubMed ID: 35314506
[TBL] [Abstract][Full Text] [Related]
2. Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.
Salvadó G; Grothe MJ; Groot C; Moscoso A; Schöll M; Gispert JD; Ossenkoppele R;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2212-2224. PubMed ID: 33521872
[TBL] [Abstract][Full Text] [Related]
3. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
4. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
5. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
6. Association of
Du J; Li A; Shi D; Chen X; Wang Q; Liu Z; Sun K; Guo T;
Neurology; 2023 Jul; 101(1):e40-e49. PubMed ID: 37188537
[TBL] [Abstract][Full Text] [Related]
7. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
8. Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer's disease.
Baek MS; Cho H; Lee HS; Lee JH; Ryu YH; Lyoo CH
Alzheimers Res Ther; 2020 Oct; 12(1):140. PubMed ID: 33129364
[TBL] [Abstract][Full Text] [Related]
9. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
11. APOE effects on regional tau in preclinical Alzheimer's disease.
Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
[TBL] [Abstract][Full Text] [Related]
12. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
13. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
[TBL] [Abstract][Full Text] [Related]
14. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity.
Costoya-Sánchez A; Moscoso A; Silva-Rodríguez J; Pontecorvo MJ; Devous MD; Aguiar P; Schöll M; Grothe MJ;
JAMA Neurol; 2023 Oct; 80(10):1051-1061. PubMed ID: 37578787
[TBL] [Abstract][Full Text] [Related]
15. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
16. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
17. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex,
Therriault J; Pascoal TA; Benedet AL; Tissot C; Savard M; Chamoun M; Lussier F; Kang MS; Berzgin G; Wang T; Fernandes-Arias J; Massarweh G; Soucy JP; Vitali P; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
Neurology; 2021 Feb; 96(7):e975-e985. PubMed ID: 33443136
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
20. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
